PNC-27 vs TUDCA
A side-by-side research comparison of PNC-27 and TUDCA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PNC-27 | TUDCA |
|---|---|---|
| Full name | PNC-27 (p53-Derived Anticancer Peptide) | Tauroursodeoxycholic Acid |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | Research compound (preclinical) | OTC supplement / Investigational |
| Mechanism | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. | Acts as a chemical chaperone that reduces endoplasmic reticulum (ER) stress, inhibits apoptosis, protects mitochondria, improves bile flow and solubility, and provides neuroprotective and cytoprotective effects. |
| Molecular weight | ~3.2 kDa | 571.81 Da |
| Half-life | Short (peptide) | Variable (enterohepatic recirculation) |
| Bioavailability | Injection (research) | Moderate oral |
| Typical dose | Not established for humans | 250-500 mg per day |
| Frequency | Research only | 1-2x daily |
| Route | Injection (research) | Oral capsule |
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
TUDCA reported benefits
- Liver protection and enzyme normalization
- Improved bile flow
- Reduced ER stress
- Mitochondrial protection
- Neuroprotective potential
- Gut barrier support
Related comparisons
Research and educational reference only. Not medical advice.